The 5q- syndrome

Rare Hematological Malignancies

Volumn , Issue , 2008, Pages 133-148

  Giagounidis, Aristoteles A N ^a   Aul, Carlo ^a  

^a ST JOHANNES HOSPITAL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMOSOME 5; CHROMOSOME DELETION; CHROMOSOME DISORDER; CLINICAL TRIAL; GENETICS; HUMAN; MYELODYSPLASTIC SYNDROME; REVIEW;

CHROMOSOME DELETION; CHROMOSOME DISORDERS; CHROMOSOMES, HUMAN, PAIR 5; CLINICAL TRIALS AS TOPIC; HUMANS; MYELODYSPLASTIC SYNDROMES;

EID: 40549141857     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-0-387-73744-7_6     Document Type: Chapter

References (48)

1. Tjio JH, Levan A. The chromosome number in man. Hereditas 1956;42:1-6.
2. Nowell PC, Hungerford DA. Chromosome studies on normal and leukemic human leukocytes. J Natl Cancer Inst 1960;25:85-109.
3. Rowley JD. Identificaton of a translocation with quinacrine fluorescence in a patient with acute leukemia. Ann Genet 1973;16(2):109-112.
4. Van den Berghe H, Cassiman JJ, David G, et al. Distinct haematological disorder with deletion of long arm of no. 15 chromosome. Nature 1974;251(5474):437-438.
5. Janssen JW, Buschle M, Layton M, et al. Clonal analysis of myelodysplastic syndromes: evidence of multipotent stem cell origin. Blood 1989;73(1):248-254.
6. Aul C, Bowen DT, Yoshida Y. Pathogenesis, etiology and epidemiology of myelodysplastic syndromes. Haematologica 1998;83(1):71-86.
7. Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982;51(2):189-199.
8. Jaffee ES, Harris NL, Stein H, et al. World Health Organization classification of tumours, pathology and genetics of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2001.
9. Giagounidis AA, Germing U, Haase S, et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del (5q) including band q31. Leukemia 2004;18(1):113-119.
10. Washington LT, Doherty D, Glassman A, et al. Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum. Leuk Lymphoma 2002;43(4):761-765.
11. Giagounidis AA, Germing U, Wainscoat JS, et al. The 5q-syndrome. Hematology 2004;19(4):271-277.
12. Giagounidis AA, Germing U, Strupp C, et al. Prognosis of patients with del (5q) MDS and complex karyotype and the possible role of lenalidomide in this patient subgroup. Ann Hematol 2005;84(9):569-571.
13. Dewald GW, Davis MP, Pierre RV, et al. Clinical characteristics and prognosis of 50 patients with a myeloproliferative syndrome and deletion of part of the long arm of chromosome 5. Blood 1985;66(1):189-197.
14. Mathew P, Tefferi A, Dewald GW, et al. The 5q-syndrome: a single-institution study of 43 consecutive patients. Blood 1993;81(4):1040-1045.
15. Kerkhofs H, Hagemeijer A, Leeksma CH, et al. The 5a-chromosome abnormality in haematological disorders: a collaborative study of 34 cases from the Netherlands. Br J Haematol 1982;52(3):365-381.
16. Van den Berghe H, Vermaelen K, Mecucci C, et al. The 5q-anomaly. Cancer Genet Cytogenet 1985;17(3):189-255.
17. Giagounidis AA, Haase S, Germing U, et al. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. Acta Haematol 2005;113(2):146-149.
18. Haase D, Germing U, Schanz J, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood 2007; DOI 10.1182/blood-2007-03-082404.
19. Jaju RJ, Boultwood J, Oliver FJ, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q-syndrome. Genes Chromosomes Cancer 1998;22(3):251-256.
20. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q-syndrome. Blood 2002;99(12):4638-4641.
21. Giagounidis AA, Germing U, Aul C. Biological and prognostic significance of chromosome 5q deletions in myeloid malignancies. Clin Cancer Res 2006;12(1):5-10.
22. Nilsson L, Astrand-Grundström I, Arvidsson I, et al. Isolation and characterization of hematopoietic progenitor/stem cells in 5q-deleted myelodysplastic syndromes: evidence for inolvement at the hematopoietic stem cell level. Blood 2000;96:2012-2021.
23. Horrigan SK, Westbrook CA, Kim AH, et al. Polymerase chain reaction-based diagnosis of del (5q) in acute myeloid leukemia and myelodysplastic syndrome identifies a minimal deletion interval. Blood 1996;88(7):2665-2670.
24. Zhao N, Stoffel A, Wang PW, et al. Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map. Proc Natl Acad Sci USA 1997;94(13):6948-6953.
25. Pellagatti A, Cazzola M, Giagounidis AA, et al. Gene expression profiles of CD34+ cells in myelodysplastic syndromes: involvement of interferon stimulated genes and correlation to FAB subtype and karyotype. Blood 2006;108(1):337-345.
26. Aivado M, Spentzos D, Germing U, et al. From the cover: Serum proteome profiling detects myelodysplastic syndromes and identifies CXC chemokine ligands 4 and 7 as markers for advanced disease. Proc Natl Acad Sci USA 2007;104(4):1307-1312.
27. Germing U, Gattermann N, Strupp C, et al. Validation of the WHO proposals for a new classification of primary myelodysplastic syndromes: a retrospective analysis of 1600 patients. Leuk Res 2000;24(12):983-992.
28. Germing U, Strupp C, Kuendgen A, et al. Prospective validation of the WHO proposals for the classification of myelodysplastic syndromes. Haematologica 2006;91(12):1596-1604.
29. Terpos E, Verrou E, Banti A, et al. Bortezomib is an effective agent for MDS/MPD syndrome with 5q-anomaly and thrombocytosis. Leuk Res 2007;31(4):559-562.
30. Howe RB, Porwit-MacDonald A, Wanat R, et al. The WHO classification of MDS does make a difference. Blood 2004;103(9):3265-3270.
31. Mannone L, Gardin C, Quarre MC, et al. High-dose darbepoetin alpha in the treatment of anaemia of lower risk myelodysplastic syndrome results of a phase II study. Br J Haematol 2006;133(5):513-519.
32. Hellstrom-Lindberg E, Gulbrandsen N, Lindberg G, et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin + granulocyte colonystimulating factor: significant effects on quality of life. Br J Haematol 2003;120(6):1037-1046.
33. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes; a metaanalysis of 205 patients from 17 studies. Br J Haematol 1995;89(1):67-71.
34. Group ICS. A randomized double-blind placebo-controlled study with subcutaneous recombinant erythropoietin in patients with low-risk myelodysplastic syndromes. Br J Haematol 1998;103(4):1070-1074.
35. Terpos E, Mougiou A, Kouraklis A, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes; a phase II trial in 281 patients. Br J Haematol 2002;118(1):174-180.
36. Hellstrom-Lindberg E, Ahlgren T, Beguin Y, et al. Treatment of anemia in myelodysplastic syndromes with granulocyte-colony stimulating factor plus erythropoietin; results from a randomized phase II study and long-term follow-up of 71 patients. Blood 1998;92(1):68-75.
37. Giagounidis AA, Haase S, Germing U, et al. Treatment of myelodysplastic syndrome with isolated del (5q) including bands q31-q33 with a combination of all-trans-retinoic acid and tocopherol-alpha: a phase II study. Ann Hematol 2005;84(6):389-394.
38. Giagounidis A, Haase S, Germing U, et al. Low-dose cytarabine in the treatment of patients with the 5q-syndrome. Onkologie 2002;25(Suppl49):XII+304.
39. Juneja HS, Jodhani M, Gardner FH, et al. Low-dose ARA-C consistently induces hematologic responses in the clinical 5q-syndrome. Am J Hematol 1994;46(4):338-342.
40. Cutler CS, Lee SJ, Greenberg P, et al. A decision analysis of allogeneic bone marrow transplantation for the myelodysplastic syndromes: delayed transplantation for low-risk myelodysplasia is associated with improved outcome. Blood 2004;104(2):579-585.
41. Musto P. Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. Leuk Res 2004;28(4):325-332.
42. Raza A, Meyer P, Dutt D, et al. Thalidomide produces transfusion independence in longstanding refractory anemias of patients with myelodysplastic syndromes. Blood 2001;98(4):958-965.
43. Strupp C, Hildebrandt B, Germing U, et al. Cytogenetic response to thalidomide treatment in three patients with myelodysplastic syndrome. Leukemia 2003;17(6):1 200-1202.
44. Mitsiades CS, Mitsiades N. CC-5013 (Celgene). Curr Opin Invest Drugs 2004;5(6):635-647.
45. List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006;355(14):1456-1465.
46. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med 2005;352(6):549-557.
47. Cheson BD, Bennett JM, Kantarjian H, et al. Report of an international working group to standardize response criteria for myelodysplastic syndromes. Blood 2000;96(12):3671-3674.
48. Stewart B, Verdugo M, Guthrie KA, Appelbaum F, Deeg HJ. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes. Br J Haematol 2003;123(5):879-85.